Acute myeloid leukemia type m2 is generally curable with standardized treatment. Acute myeloid leukemia type m2 is a partially differentiated type of acute myeloid leukemia, whether it can be cured or not is related to the leukemia risk stratification, age of onset, treatment, etc. Generally, the lower the risk stratification and the younger the age of onset, the higher the rate of complete remission. 90% of the children, 70% of the young adults, 60% of the middle-aged people, and 25% of the elderly people can obtain complete remission with the current therapies. Specific medications include cytarabine, zorubicin, and decitabine. Acute myeloid leukemia type m2 induction therapy remission rates and duration of remission also decrease with increasing age at first diagnosis. Some patients have the possibility of relapse after treatment. Therefore, once the diagnosis is confirmed, the treatment should be actively standardized under the guidance of physicians and followed up regularly.